Research into B-cell non-Hodgkin lymphoma is picking up speed. More than seventy-five companies are now running over eighty experimental therapies through clinical trials. This new push is more than just a numbers jump. It marks a clear shift in how the industry is tackling one of the most common types of lymphoma.
IASO208, a CD20-targeted in vivo CAR-T therapy, recently received FDA IND clearance and is set to move directly into Phase Ib trials in the United States for adults with relapsed or refractory B-cell non-Hodgkin lymphoma.
These studies are just a small part of a crowded and fast-moving field. The pipeline includes big names like Xencor, MEI Pharma, Celldex Therapeutics, TG Therapeutics, Shanghai Unicar-Therapy Bio-medicine Technology, Chia Tai Tianqing Pharmaceutical Group, Mustang Bio, Novartis, Loxo Oncology, Genmab, Nkarta, Nurix Therapeutics, and Prelude Therapeutics. They are working on a wide range of drugs. Some are well known, like bendamustine hydrochloride injection, ibrutinib, cyclophosphamide, mitoxantrone, and vincristine. Others are newer, such as glofitamab, atezolizumab, and obinutuzumab.
Several new therapies are getting extra attention. Daiichi Sankyo’s valemetostat, an EZH1/2 dual inhibitor, is in phase II for blood cancers including NHL. Mustang Bio’s MB-106, a CD20-targeted autologous CAR T cell therapy, is moving through Phase I/II. Caribou Biosciences is testing CB-010, an allogeneic anti-CD19 CAR-T cell therapy with PD-1 knockout, in Phase I. Lantern Pharma’s LP-284, a small molecule that targets DNA damage repair mutations, is also in Phase I and has orphan drug status.
IASO208 is already undergoing an investigator-initiated, single-arm, open-label dose-exploration study in China to assess safety, tolerability, and preliminary efficacy in patients with relapsed or refractory B-cell malignancies.
B-cell non-Hodgkin lymphoma starts from abnormal B lymphocytes. It makes up over 85% of all NHL cases. The main subtypes include diffuse large B-cell lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, and Burkitt lymphoma. Most patients have painless swollen lymph nodes, fever, night sweats, tiredness, weight loss, itchy skin, and pain. These symptoms show why better and more targeted treatments are needed.
At the SOHO 2026 conference, results from the phase 3 frontMIND study showed that adding tafasitamab and lenalidomide to standard R-CHOP therapy helped patients with untreated high-risk diffuse large B-cell lymphoma or high-grade B-cell lymphoma live longer without their disease getting worse. This has given more energy to research in aggressive B-cell lymphomas, as reported by CancerNetwork coverage.
DelveInsight’s latest report does more than just list the pipeline. It breaks down drug development by product type, stage, how the drugs are given, and molecule type. The report also covers partnerships, licensing deals, and market trends. It even tracks pipeline drugs that are no longer active, giving a full picture of the changing competitive field.
With so many companies and different drug approaches, the B-cell non-Hodgkin lymphoma pipeline is getting more complex and full of new chances. The current rush of clinical trials is not just adding more treatment options. It is making the race for better results and commercial success even tougher. For patients and doctors, this could mean more personalized and effective treatments in the future. But it will also depend on strong evidence and smart moves from the companies leading the way.
